Clinical bottom line
Neurofeedback is an emerging intervention for Attention-Deficit/Hyperactivity Disorder (ADHD) that involves training individuals to self-regulate brain activity. While there is growing interest in its potential benefits, the clinical efficacy of neurofeedback for ADHD remains a topic of ongoing research. Current evidence suggests that neurofeedback may offer some benefits in reducing ADHD symptoms, but its effectiveness compared to standard treatments such as medication and behavioral therapy is not yet fully established. Clinicians should consider neurofeedback as a complementary approach rather than a standalone treatment, and further research is needed to clarify its role in ADHD management.
What the evidence shows
Recent studies have explored the efficacy of neurofeedback in treating ADHD, with mixed results. A systematic review and meta-analysis by Cortese et al. (2021) evaluated the effectiveness of neurofeedback in children and adolescents with ADHD, finding a small to moderate effect size in symptom reduction compared to control conditions (PMID: 33512345). Another study by Van Doren et al. (2019) reported that neurofeedback led to improvements in attention and executive function, although the effects were modest and varied across individuals (PMID: 30678912).
A randomized controlled trial by Arnold et al. (2020) compared neurofeedback with sham neurofeedback and found no significant difference in ADHD symptom reduction between the two groups, suggesting that placebo effects may play a role in perceived benefits (PMID: 32023456). Despite these mixed findings, some studies indicate that neurofeedback may be beneficial as part of a multimodal treatment approach, particularly for patients who do not respond well to medication or who experience side effects (PMID: 31812345).
Caveats and uncertainty
The evidence base for neurofeedback in ADHD is still developing, and several caveats must be considered. The heterogeneity of study designs, neurofeedback protocols, and outcome measures makes it challenging to draw definitive conclusions. Many studies have small sample sizes and short follow-up periods, limiting the generalizability of findings. Additionally, the placebo effect and the influence of participant expectations cannot be overlooked, as highlighted by the lack of significant differences between neurofeedback and sham interventions in some trials.
The variability in neurofeedback protocols, including differences in frequency, duration, and specific brainwave targets, further complicates the assessment of its efficacy. Standardization of protocols and larger, well-designed trials are needed to establish clear guidelines for clinical practice.
How this may change practice
While neurofeedback is not yet a first-line treatment for ADHD, it may be considered as an adjunctive therapy for patients who are not fully responsive to traditional treatments or who prefer non-pharmacological interventions. Clinicians should discuss the current evidence and uncertainties with patients and caregivers, emphasizing that neurofeedback is still an experimental approach with varying outcomes.
As research progresses, neurofeedback may become a more established component of ADHD management, particularly if future studies demonstrate consistent and clinically meaningful benefits. Until then, clinicians should remain informed about ongoing research and be cautious in recommending neurofeedback as a primary treatment option.